Founder of Nova Biosciences. Co-author (with Dr. Mark Lee Spencer) of the 2110 TIGR-Tas paper — a nanoscale gene-editing delivery platform that achieved 100% clinical clearance of prion, Huntington’s, and amyloid-associated neurodegeneration in trial. The platform was not commercialized; Earth-side health systems already had cheaper, established standard-of-care treatments for all three conditions.
Moved from Dome 1 to Dome 4 around 2118, redirecting the TIGR-Tas platform toward space radiation damage repair — a market with no existing competitors. During extended trials, the redesigned platform demonstrated an unplanned anti-aging effect: telomere elongation and partial reversal of age-associated DNA methylation patterns. Resigned her UN research post to accept Omani private capital and found Nova Biosciences, developing the platform as Project Prometheus.
Gave a public interview to Luna Interplanetary News in 2124 explaining the platform’s origin, the commercial failure of the original neurodegenerative application, and the unplanned anti-aging discovery. By 2148, at age 73, she had been on her own protocol for 26 years — her cellular markers reading as late-thirties — and described herself as “my own longest-running human trial.” Nova Biosciences by then operated seven Omani-licensed stations across three classes (Hayat, Rafah, Shifa) system-wide, with over 100,000 active subscribers, most Earth-origin, at ~12,500 UN credits per visit for early starters. She acknowledged the treatment’s exclusivity: “I didn’t start this company to build something only a hundred thousand people could ever access.”
In the March 2169 Prometheus II announcement, at 94 and still looking forty, Murphy conceded the first generation’s limit — the neuroentropic cascade, the accumulation of fixed somatic mutations in post-mitotic neurons and cardiomyocytes that the Luna University mortality working group named in 2167, with first subscriber deaths already on record between 150 and 200 — and announced the Repair Core, a second-generation payload that repairs those mutations in place against the patient’s own germline reference. She framed it as answering the industry’s claim that somatic mutation is irreversible: “Entropy is not irreversible if you have a sufficiently precise repair mechanism.” She closed by naming herself the first Repair Core patient — “My neurons are being repaired as I speak to you” — and promised to keep doubling the ceiling.
Sources
- Luna Interplanetary News: Murphy Nanobot Interview (2124)
- Nova Biosciences — Internal Technical Dossier: Project Prometheus (2122)
- LIN Sponsored Feature: Dr. Amelia T. Murphy on Twenty-Six Years of Looking Thirty (2148)
- Nova Biosciences — Prometheus II: The Repair Core. We’ve Doubled the Ceiling (2169)